Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2021-11-23 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞关于向特定对象发行股票申请获得中国证券监督管理委员会同意注册批复的公告
Capital/Financing Update Classification · 100% confidence The document is an official announcement from Beijing Sinocelltech Biotech Co., Ltd. regarding the approval from the China Securities Regulatory Commission (CSRC) for the company's application to issue shares to specific investors. It includes details about the registration approval, validity period, and compliance requirements. The content focuses on the company's capital raising activity through a specific share issuance. There are no financial statements or detailed financial performance data, so it is not an Annual Report or Interim Report. The document is clearly about a capital/financing update related to share issuance to specific investors, which fits the Capital/Financing Update (CAP) category.
2021-11-23 Chinese
北京神州细胞生物技术集团股份公司2021年度向特定对象发行A股股票募集说明书（注册稿）
Capital/Financing Update Classification · 95% confidence The document is titled as an "Annual Private Placement A Share Stock Offering Prospectus" for Beijing Sinocelltech Group Limited for the year 2021. It contains detailed information about the company, its shareholders, controlling persons, business model, risk factors, and the specifics of the stock issuance. The document is lengthy (15,000 characters) and includes comprehensive disclosures typical of a prospectus related to a capital raising event. This is not a general annual report or earnings release but a detailed offering document related to a specific capital raising transaction. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2021-11-23 Chinese
神州细胞自愿披露关于控股子公司重组新冠病毒疫苗产品SCTV01C获得药物临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding its controlling subsidiary receiving approval from the National Medical Products Administration for clinical trial authorization of a recombinant COVID-19 vaccine product (SCTV01C). The text includes details about the clinical trial approval, product description, risk warnings, and regulatory compliance statements. It is an official announcement about a regulatory approval event rather than a financial report, earnings release, or management discussion. The document length is short (1781 characters) and it does not contain financial data or detailed financial analysis. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about clinical trial approval and associated risks, which does not fit other specific categories like earnings, capital updates, or management changes.
2021-11-12 Chinese
神州细胞2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2021 年第三季度报告" which translates to "2021 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2021. The document explicitly states it is a quarterly report and includes unaudited financial statements for the period ending September 30, 2021. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2021
2021-10-27 Chinese
北京市金杜律师事务所关于北京神州细胞生物技术集团股份公司2021年度向特定对象发行A股股票的补充法律意见书（四）
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm (北京市金杜律师事务所) regarding a specific issuance of A shares by 北京神州细胞生物技术集团股份公司 in 2021. It references regulatory frameworks related to securities law, company law, and stock exchange listing rules. The document is a supplementary legal opinion (补充法律意见书（四）) related to the issuance and listing process on the STAR Market (科创板). It contains detailed legal verification and compliance statements about the issuance, including clarifications on real estate business involvement and fund usage. The document is not a financial report, earnings release, or management discussion but a legal opinion supporting a capital raising event. This fits the category of Capital/Financing Update (CAP), as it relates to a specific share issuance and legal compliance for that financing activity. The document length (8455 characters) and content confirm it is a substantive legal opinion, not merely an announcement or certification, so it is not RNS or RPA. Therefore, the best classification is CAP with high confidence.
2021-10-26 Chinese
关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的发行注册环节反馈意见落实函的回复报告
Capital/Financing Update Classification · 95% confidence The document is a detailed reply report from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. addressing feedback from the China Securities Regulatory Commission and the Shanghai Stock Exchange regarding a specific stock issuance application. It includes detailed disclosures about the issuance method, pricing, lock-up periods, and clarifications about the company's and its subsidiaries' business scope, specifically confirming no involvement in real estate business. The document also contains legal and sponsor institution opinions, confirmations, and declarations by the company's chairman and the sponsor's chairman. The content is regulatory in nature, related to a capital raising event (a private placement of shares), and involves detailed compliance and disclosure information. It is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a regulatory filing related to a capital issuance process, specifically addressing regulatory feedback and compliance. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (8782 characters) and detailed content support this classification with high confidence.
2021-10-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.